510 related articles for article (PubMed ID: 15246511)
1. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
3. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Sader HS; Jones RN; Stilwell MG; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):181-6. PubMed ID: 16105562
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
Fritsche TR; Jones RN
Int J Antimicrob Agents; 2004 Dec; 24(6):567-71. PubMed ID: 15555879
[TBL] [Abstract][Full Text] [Related]
9. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):202-12. PubMed ID: 19321284
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
Gales AC; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
Betriu C; Rodríguez-Avial I; Gómez M; Culebras E; López F; Alvarez J; Picazo JJ;
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):437-44. PubMed ID: 16949245
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
15. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
[TBL] [Abstract][Full Text] [Related]
16. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
17. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
Tubau F; Liñares J; Rodríguez MD; Cercenado E; Aldea MJ; González-Romo F; Torroba L; Berdonces P; Plazas J; Aguilar L; Delgado A; García-Escribano N;
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):308-13. PubMed ID: 20022193
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
Gales AC; Jones RN; Andrade SS; Pereira AS; Sader HS
Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia.
Bradford PA; Petersen PJ; Tuckman M; Jones CH
Clin Microbiol Infect; 2008 Sep; 14(9):882-6. PubMed ID: 18844692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
